205 related articles for article (PubMed ID: 29022233)
41. [Cardiotoxicity of antineoplastic drugs].
Drzewoski J; Kasznicki J
Acta Haematol Pol; 1992; 23(2):79-86. PubMed ID: 1488864
[TBL] [Abstract][Full Text] [Related]
42. Cardiac involvement in patients with hematologic malignancies.
Allegra A; Alonci A; Russo S; Cannavò A; Penna G; D'Angelo A; Bellomo G; Musolino C
J Investig Med; 2010 Oct; 58(7):859-74. PubMed ID: 20683345
[TBL] [Abstract][Full Text] [Related]
43. Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.
Kanz BA; Pollack MH; Johnpulle R; Puzanov I; Horn L; Morgans A; Sosman JA; Rapisuwon S; Conry RM; Eroglu Z; Johnson DB
J Immunother Cancer; 2016; 4():60. PubMed ID: 27777770
[TBL] [Abstract][Full Text] [Related]
44. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.
Santoni M; Guerra F; Conti A; Lucarelli A; Rinaldi S; Belvederesi L; Capucci A; Berardi R
Cancer Treat Rev; 2017 Sep; 59():123-131. PubMed ID: 28818671
[TBL] [Abstract][Full Text] [Related]
45. Pathogenesis of cardiotoxicity induced by anthracyclines.
Elliott P
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
[TBL] [Abstract][Full Text] [Related]
46. Cardiovascular toxicity of biologic agents for cancer therapy.
Bhave M; Akhter N; Rosen ST
Oncology (Williston Park); 2014 Jun; 28(6):482-90. PubMed ID: 25134321
[TBL] [Abstract][Full Text] [Related]
47. State of the art review: Chemotherapy-induced cardiotoxicity in children.
Loar RW; Noel CV; Tunuguntla H; Colquitt JL; Pignatelli RH
Congenit Heart Dis; 2018 Jan; 13(1):5-15. PubMed ID: 29226596
[TBL] [Abstract][Full Text] [Related]
48. Myocardial Strain Is Associated with Adverse Clinical Cardiac Events in Patients Treated with Anthracyclines.
Ali MT; Yucel E; Bouras S; Wang L; Fei HW; Halpern EF; Scherrer-Crosbie M
J Am Soc Echocardiogr; 2016 Jun; 29(6):522-527.e3. PubMed ID: 27068546
[TBL] [Abstract][Full Text] [Related]
49. May-Thurner syndrome and the risk of pulmonary embolism in patients with acute deep venous thrombosis.
Jin S; Sun Z; Li X; Jian T; Jin X; Li S; Wang G; Ma C; Cui K; Xu P
J Vasc Surg Venous Lymphat Disord; 2018 Jul; 6(4):433-440.e1. PubMed ID: 29909851
[TBL] [Abstract][Full Text] [Related]
50. The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours.
Yilmaz B; Erdem D; Teker F; Goren I; Yildirim B; Kut E; Sarikaya D; Atay MH; Yucel I
J Int Med Res; 2016 Jun; 44(3):627-38. PubMed ID: 27048386
[TBL] [Abstract][Full Text] [Related]
51. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
[TBL] [Abstract][Full Text] [Related]
52. Thromboembolic complications following a first isolated episode of superficial vein thrombosis: a cross-sectional retrospective study.
Bell LN; Berg RL; Schmelzer JR; Liang H; Mazza JJ; Kanth R; Bray CL; Zaldivar CB; Yale SH
J Thromb Thrombolysis; 2017 Jan; 43(1):31-37. PubMed ID: 27565478
[TBL] [Abstract][Full Text] [Related]
53. Myocardial Protection During Cardiotoxic Chemotherapy.
Witteles RM; Bosch X
Circulation; 2015 Nov; 132(19):1835-45. PubMed ID: 26553713
[No Abstract] [Full Text] [Related]
54. Different characteristics and prognostic impact of deep-vein thrombosis / pulmonary embolism and intraabdominal venous thrombosis in colorectal cancer patients.
Choi S; Lee KW; Bang SM; Kim S; Lee JO; Kim YJ; Kim JH; Park YS; Kim DW; Kang SB; Kim JS; Oh D; Lee JS
Thromb Haemost; 2011 Dec; 106(6):1084-94. PubMed ID: 22072215
[TBL] [Abstract][Full Text] [Related]
55. Approach to cardio-oncologic patients with special focus on patients with cardiac implantable electronic devices planned for radiotherapy: results of the European Heart Rhythm Association survey.
Lenarczyk R; Potpara TS; Haugaa KH; Deharo JC; Hernandez-Madrid A; Del Carmen Exposito Pineda M; Kiliszek M; Dagres N
Europace; 2017 Sep; 19(9):1579-1584. PubMed ID: 28934410
[TBL] [Abstract][Full Text] [Related]
56. Anthracycline cardiotoxicity.
Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
[TBL] [Abstract][Full Text] [Related]
57. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
Jensen SA; Sørensen JB
Cancer Chemother Pharmacol; 2006 Oct; 58(4):487-93. PubMed ID: 16418875
[TBL] [Abstract][Full Text] [Related]
58. Pulmonary embolism without deep venous thrombosis.
Schwartz T; Hingorani A; Ascher E; Marks N; Shiferson A; Jung D; Jimenez R; Jacob T
Ann Vasc Surg; 2012 Oct; 26(7):973-6. PubMed ID: 22749324
[TBL] [Abstract][Full Text] [Related]
59. Role of biomarkers in chemotherapy-induced cardiotoxicity.
Cardinale D; Sandri MT
Prog Cardiovasc Dis; 2010; 53(2):121-9. PubMed ID: 20728699
[TBL] [Abstract][Full Text] [Related]
60. [Cardiovascular complications of cancers and anti-cancer therapy].
Vyskočil J; Petráková K; Jelínek P; Furdek M
Vnitr Lek; 2017; 63(3):200-209. PubMed ID: 28379023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
